Astellas/Seagen prepare full US filing of bladder cancer dru...

Astellas and Seagen have the data they need for a full licence for their bladder cancer drug Padcev in the US, based on trial results announced over the weekend.

Seattle Genetics says data backs Padcev combo for first-line...

FDA backs Astellas/Seattle Genetics bladder cancer drug

The FDA has quickly okayed Astellas and Seattle Genetics’ advanced bladder cancer drug enfortumab vedotin, one of the stars of this year’s ASCO conference that was considered an almost dead